CUPERTINO, Calif., Sept. 02, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights
-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million -Expected to Initiate Pivotal Phase 3 Clinical Trial in Schizophrenia in Q4'21 -$35.8 Million in Cash as of June 30, 2021 CUPERTINO, Calif., Aug. 16, 2021 --...
Reviva Added to Russell Microcap® Index
CUPERTINO, Calif., June 28, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, "Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering
CUPERTINO, Calif., May 26, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS),...
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
Met endpoints for safety and efficacy in 234 patients' clinical trial with Acute Schizophrenia or Schizoaffective DisorderMet primary endpoint of reduction in Positive and Negative Syndrome Scale (PANSS) total score for SchizophreniaMitigated positive symptoms and...
Reviva Pharmaceuticals Holdings, Inc. Reports 2020 Financial Results and Provides Corporate Update
-Closed Merger with Tenzing Acquisition Corp and publicly listed on NASDAQ Capital Market- -Plans to initiate a pivotal Phase 3 trial in schizophrenia in mid-2021, assuming fundraising goals achieved- CUPERTINO, Calif., March 22, 2021 -- Reviva Pharmaceuticals...
Reviva Pharmaceuticals Holdings, Inc. to Present at the Maxim Group Inaugural 2021 Emerging Growth Virtual Conference
CUPERTINO, Calif., March 11, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, "Reviva" or the "Company"), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference
CUPERTINO, Calif., March 04, 2021 -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, "Reviva") today announced that its wholly owned subsidiary Reviva Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing...
Reviva Pharmaceuticals, Inc. and Tenzing Acquisition Corp. Complete their Business Combination and Trade as Reviva Pharmaceuticals Holdings, Inc.
Combined Company to Trade on NASDAQ Post-closing under Tickers: RVPH and RVPHW NEW YORK and CUPERTINO, Calif., Dec. 14, 2020 -- Reviva Pharmaceuticals Holdings, Inc., a Delaware corporation ("Reviva Holdings"), as the successor to Tenzing Acquisition Corp., a special...